INHA

Across TCGA pan-cancer cohorts, INHA Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated INHA data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher INHA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated INHA expression acts as an unfavorable survival marker.

LUSC, SARC, and UCEC are the cancer types where INHA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.191	0.634	.001	24	view →
SARC	OS	Median	All	0.183	0.839	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

INHA–LUSC (OS)

Open the LUSC breakdown →